Balyasny Asset Management LLC Collegium Pharmaceutical, Inc Transaction History

Balyasny Asset Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$21.16 - $30.8 $313,548 - $456,394	14,818 New	14,818 $456,000
Q4 2022 Feb 14, 2023	BUY	$16.14 - $23.55 $2.71 Million - $3.95 Million	167,816 New	167,816 $3.89 Million
Q1 2020 May 15, 2020	SELL	$13.89 - $25.45 $147,484 - $270,228	-10,618 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$10.7 - $22.24 $113,612 - $236,144	10,618 New	10,618 $219,000
Q4 2018 Feb 14, 2019	SELL	$14.78 - $19.68 $498,263 - $663,452	-33,712 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$14.16 - $24.3 $477,361 - $819,201	33,712 New	33,712 $497,000
Q2 2018 Aug 14, 2018	SELL	$21.79 - $28.29 $381,760 - $495,640	-17,520 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$18.15 - $29.21 $317,988 - $511,759	17,520 New	17,520 $448,000

254

36.9M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.12B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.